Company announced positive interim data from and the expansion of Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery.
ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ REGENXBIO Inc. today announced that it will present in a fireside chat at Chardan s 6th Annual Genetic Medicines Conference on Tuesday, October 4th,. | September 27, 2022
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 20th Annual.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium,.